Company
Peptone was born out of 30 years of combined academic research into Intrinsically Disordered Proteins at Cambridge, Oxford, ETH Zurich and University of Groningen.
We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
The focal point of our interdisciplinary team of researchers is intersection of physics, molecular biology and next-generation supercomputing.
We use highly sophisticated structural analysis techniques, such as nuclear magnetic resonance (NMR) spectroscopy and hydrogen-exchange mass spectrometry (HDX-MS), which can measure the physical properties of dynamic, disordered proteins as they move.
This data is then fed into Peptone’s supercomputer, which applies physical modeling methods and machine learning algorithms to create millions of simulations of the most likely conformations of a particular disordered protein or protein regions and the best way to target them with drugs. These predictions are then tested in the lab and the results are fed back in for further cycles of refinement, generating viable drug candidates to take forward for further development.
Our protein biophysics research facility is located in Bellinzona, Switzerland, with the company’s experimentalists and management based there.
Peptone’s theoretical and BD team sits at our corporate HQ in London, UK.
Peptone’s NVIDIA DGX A100 supercomputer is located at Verne Global’s data center campus in Keflavik, Iceland, where it runs on 100% renewable geothermal and hydroelectric energy.
Alex Bisioti
Business Development and Strategic Intelligence Manager
Dr. Sasha Soldati
Bioassays & Functional Screenings Scientist
Fahad Arshad
Finance Manager
Dr. Babette Schade
Director of Biology & Project Lead in Biology
Dr. Andrea Rinaldi
Technical Laboratory Advisor
Dr. Thomas Alanine
Principal Medicinal Chemist
Dr. Daniele Peterle
Mass Spectrometry Senior Scientist
Dr. Dmitry Ryzhenkov
Protein Production Group Leader
Albert Chung
Machine Learning Research Engineer
Pietro Puricelli
IT Manager
Rachel Jenkins
Director of Finance
Dr. Matthew Lakins
Director of Disease Biology
Valentina Ceserani
Bioassays & Functional Screenings Scientist
Dr. Andrew Allen
Chairman of The Board
Dr. David Lowe
SVP of Biologics
Dr. Patrik Foerch
Chief Scientific Officer
Dr. Anastasiya Sybirna
Board Observer
Susana Lopez Alcantara
Discovery Lead
Dr. Sandro Bottaro
Principal Scientist Computational Biophysics
Fabio Airoldi
Head of Software and Data Engineering
Chiara Toscano
Joint Operations Manager
Gemma Williams
Executive Assistant
Dr. Gabriella Orlando
Biosafety Officer
Jeremy Sohn
Board and Executive Advisor
Dr. Elia Gamba
Senior Protein Scientist
Dr. Francis Ho
Venture Capital Investor
Dr. Alex Pasteur
Venture Capital Investor
Andrew Hedin
Venture Capital Investor
Steve Crossan
Entrepreneur and Advisor
Dr. Patrick Kunz
Head of Experimental Biophysics
Prof. Emanuele Paci
Computational Physics Researcher
Dr. George Golumbeski
Non-Executive Director
Dr. Falk Hoffmann
Integrative Modelling Lead
Dr. Benjamin Owens
Chief Business Officer
Dr. Istvan Redl
Machine Learning Lead
Oliver Dutton
Development and HPC Lead
Dr. Louie Henderson
Structural Biochemistry Lead
Dr. Kamil Tamiola
Chief Executive Officer and Founder
Hussein Kanji
Venture Capital Investor
Carlo Fisicaro
Chief Technology Officer
Dr. Rudy Rubini
Protein Purification Scientist
Georgina Camps Paradell
Protein Purification Scientist
Matteo Cerrina
Protein Analytics Scientist
Dr. Joseph Casson
Senior Antibody Engineering Scientist
Turlough Nevin
Project Manager
Dr. Flavia Giamogante
Bioassays & Functional Screenings Scientist
Marta Fiocco
HR Manager
Dr. Michael Habeck
Protein Purification Scientist
Heidi Derks
Senior Bioassays & Functional Screenings Scientist
Dr. Janek Kibat
Director of Operations
Dr. Michele Invernizzi
Computational Scientist
Nathalie Wyss
Protein Analytics Scientist